Madrigal Pharmaceuticals, Inc. MDGL Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s total liabilities & equity?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported total liabilities & equity of $1.23B in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s total liabilities & equity increased by 23.1% year-over-year, from $996.63M to $1.23B.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s total liabilities & equity has grown at a 34.4% compound annual growth rate (CAGR), from $287M to $1.26B.
- What does total liabilities & equity mean?
- The total size of the company's balance sheet, representing all assets financed by debt or equity.
- How do you interpret total liabilities & equity?
- Growth in this metric generally indicates the expansion of the company's asset base and operational scale.
- How does total liabilities & equity compare across companies?
- Used as a baseline to compare the relative size and capital intensity of peers.